HOW IT WORKS:
How can you tailor therapeutic strategies based on disease aggressiveness?
VeriStrat® is a blood-based predictive and prognostic proteomic test for patients with advanced non-small cell lung cancer who test negative for EGFR mutations (EGFR wild-type) or whose EGFR mutation status is unknown.
VeriStrat assesses disease aggressiveness, classifying patients as either VeriStrat Good or VeriStrat Poor.
- Blood test
- 72 hour results
- VeriStrat classification is also predictive of differential treatment benefit for single agent therapy
- Medicare covers VeriStrat testing for lung and certain other cancers; coverage may also be available through other payers
VeriStrat identifies the host patient response to the tumor by measuring several acute phase reactant proteins in the blood. VeriStrat Poor signature correlates with a more aggressive disease; VeriStrat Good signature correlates with a more favorable prognosis. In addition to being prognostic, VeriStrat is predictive of differential treatment benefit when selecting between single-agent treatment options.